Protelos (strontium ranelate), the only osteoporosis therapy to simultaneously increase bone formation and decrease bone resorption, was launched today by Servier Laboratories. The first in a new class of osteoporosis therapies called dual action bone agents (DABAs), Protelos is licenced for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral and hip fracture.
Recent Blog Post
Diet high in protein linked with loss of muscle
9th March 2023 – By Aaruthy Suthahar Researchers from TwinsUK have found that rather than being protective, high protein intake...
Can use of proton pump inhibitors increase your risk of fractures?
1st February 2023 – By Aaruthy Suthahar Researchers from TwinsUK have found that taking proton pump inhibitors is linked with...
How much of a boost do “booster” COVID-19 jabs give?
26th January 2022 – By Aaruthy Suthahar Scientists have found the “booster” COVID-19 vaccine programme led to a large boost...